Novus Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, NVUS, Novus Therapeutics Inc, priceseries

Novus Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
13.76
Close
12.66
High
14.23
Low
12.65
Previous Close
13.90
Daily Price Gain
-1.24
YTD High
4860.00
YTD High Date
Sep 17, 2014
YTD Low
4.50
YTD Low Date
Mar 20, 2020
YTD Price Change
-3836.46
YTD Gain
-99.67%
52 Week High
14.23
52 Week High Date
Mar 8, 2021
52 Week Low
12.65
52 Week Low Date
Mar 8, 2021
52 Week Price Change
0.00
52 Week Gain
0.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 16. 2018
61.92
Mar 2. 2018
65.51
9 Trading Days
5.80%
Link
LONG
Mar 12. 2018
75.96
Mar 22. 2018
90.17
8 Trading Days
18.70%
Link
LONG
May 14. 2018
102.78
May 15. 2018
109.80
1 Trading Days
6.83%
Link
LONG
May 18. 2018
110.16
May 30. 2018
118.86
7 Trading Days
7.90%
Link
LONG
Jan 31. 2019
77.40
Feb 1. 2019
83.52
1 Trading Days
7.91%
Link
LONG
Dec 27. 2019
11.16
Dec 30. 2019
11.76
1 Trading Days
5.41%
Link
LONG
Jan 8. 2020
13.14
Jan 13. 2020
13.88
3 Trading Days
5.65%
Link
LONG
Apr 16. 2020
6.93
Apr 17. 2020
7.43
1 Trading Days
7.14%
Link
LONG
Apr 20. 2020
8.24
May 5. 2020
11.08
11 Trading Days
34.41%
Link
LONG
Oct 28. 2020
17.49
Nov 6. 2020
21.12
7 Trading Days
20.74%
Link
Company Information
Stock Symbol
NVUS
Exchange
NasdaqGM
Company URL
http://www.tokaipharmaceuticals.com
Company Phone
949-238-8090
CEO
Jodie P. Morrison
Headquarters
California
Business Address
19900 MACARTHUR BLVD., SUITE 550, IRVINE, CA 92612
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001404281
About

Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA.

Description

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company's androgen receptor degradation agents drug discovery program is focused on identifying and developing compounds for patients with androgen receptor signaling diseases, including prostate cancer. Tokai Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading